<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918173</url>
  </required_header>
  <id_info>
    <org_study_id>ATN-106</org_study_id>
    <nct_id>NCT04918173</nct_id>
  </id_info>
  <brief_title>Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery</brief_title>
  <official_title>A Multicentre, Prospective, Open-label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events&#xD;
      (TEEs) in patients with congenital antithrombin deficiency under cover of Atenativ for&#xD;
      surgical procedures or parturition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombotic event incidence</measure>
    <time_frame>Up to day 30 post treatment initiation</time_frame>
    <description>The primary objective of this study is to assess the incidence of the composite of TEs and TEEs in patients with congenital antithrombin deficiency under cover of Atenativ for surgical procedures or parturition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose Pharmacokinetics of Atenativ: Area under the curve (AUCnorm(0-∞))</measure>
    <time_frame>Up to day 14 post PK infusion</time_frame>
    <description>Assess the area under the curve (AUCnorm(0-∞)) of Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Pharmacokinetics of Atenativ: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion</time_frame>
    <description>Assess the maximum plasma concentration (Cmax) after a single dose of Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Pharmacokinetics of Atenativ: Half-life (t1/2)</measure>
    <time_frame>Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion</time_frame>
    <description>Assess the half-life (t1/2) after a single dose of Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Pharmacokinetics of Atenativ: Mean residence time (MRT)</measure>
    <time_frame>Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion</time_frame>
    <description>Assess the mean residence time (MRT) after a single dose of Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Pharmacokinetics of Atenativ: Clearance (CL)</measure>
    <time_frame>Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion</time_frame>
    <description>Assess the clearance (CL) after a single dose of Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Pharmacokinetics of Atenativ: Incremental in vivo recovery (IVR)</measure>
    <time_frame>Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion</time_frame>
    <description>Assess the Incremental in vivo recovery after a single dose of Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Pharmacokinetics of Atenativ: Volume of distribution at steady state (Vss)</measure>
    <time_frame>Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion</time_frame>
    <description>Assess the volume of distribution at steady state (Vss) after a single dose of Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Pharmacokinetics of Atenativ: Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion</time_frame>
    <description>Assess the time to reach Maximum Plasma Concentration (Tmax) after a single dose of Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10. Coagulation parameters: Activated partial thromboplastin time [aPTT]</measure>
    <time_frame>Up to day 7 post treatment initiation</time_frame>
    <description>Assess activated partial thromboplastin time [aPTT] in patients with congenital antithrombin deficiency undergoing surgical procedures or parturition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters: Prothrombin time [PT]</measure>
    <time_frame>Up to day 7 post treatment initiation</time_frame>
    <description>Assess prothrombin time [PT] in patients with congenital antithrombin deficiency undergoing surgical procedures or parturition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters: International normalised ratio [INR]</measure>
    <time_frame>Up to day 7 post treatment initiation</time_frame>
    <description>Assess international normalised ratio [INR] in patients with congenital antithrombin deficiency undergoing surgical procedures or parturition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters: Fibrinogen level</measure>
    <time_frame>Up to day 7 post treatment initiation</time_frame>
    <description>Assess fibrinogen in patients with congenital antithrombin deficiency undergoing surgical procedures or parturition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: Number of adverse events (AEs)</measure>
    <time_frame>Up to day 30 post treatment initiation</time_frame>
    <description>Number of adverse events (AEs) following treatment with Atenativ in patients with congenital antithrombin deficiency</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Congenital Antithrombin Deficiency</condition>
  <arm_group>
    <arm_group_label>Atenativ treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single intravenous infusion of Atenativ for PK analysis. Patients will receive a single intravenous dose followed by maintenance doses administered every 24 hours for approximately 2-7 days for surgical patients and approximately 5 days for parturients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenativ</intervention_name>
    <description>Antithrombin concentrate</description>
    <arm_group_label>Atenativ treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male or female patients ≥18 and ≤80 years of age&#xD;
&#xD;
          2. Documented congenital antithrombin deficiency, defined by plasma level of antithrombin&#xD;
             ≤60%&#xD;
&#xD;
          3. Personal or family history of TEs or TEEs&#xD;
&#xD;
          4. For the Treatment Phase: either a) non-pregnant surgical patients scheduled for&#xD;
             elective surgical procedure(s) known to be associated with a high risk for occurrence&#xD;
             of TEs or TEEs, or b) pregnant patients of at least 27 weeks gestational age who are&#xD;
             scheduled for caesarean section or delivery&#xD;
&#xD;
          5. For female patients of childbearing potential entering the PK Phase who are not known&#xD;
             to be pregnant, and for female surgical patients of childbearing potential entering&#xD;
             the Treatment Phase for any procedure other than caesarean section or delivery, a&#xD;
             negative urine pregnancy test at screening and at baseline&#xD;
&#xD;
          6. Patient has provided informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Requires emergency surgery or emergency caesarean section&#xD;
&#xD;
          2. Has undergone surgery within the last 6 weeks&#xD;
&#xD;
          3. History or suspicion of another hereditary thrombophilic disorder other than&#xD;
             antithrombin deficiency (e.g., activated protein C [APC] resistance/Factor V Leiden,&#xD;
             Protein S or C deficiency, prothrombin gene mutation [G20210A], or acquired [lupus&#xD;
             anticoagulant] thrombophilic disorder)&#xD;
&#xD;
          4. Malignancies, renal failure, or severe liver disease (aspartate aminotransferase&#xD;
             [ASAT] &gt;5 times the upper limit of normal)&#xD;
&#xD;
          5. Body mass index &gt;40 kg/m2&#xD;
&#xD;
          6. Known hypersensitivity or allergic reaction to antithrombin or any of the excipients&#xD;
             in Atenativ&#xD;
&#xD;
          7. History of anaphylactic reaction(s) to blood or blood components&#xD;
&#xD;
          8. Refusal to receive transfusion of blood-derived products&#xD;
&#xD;
          9. Administration of any antithrombin concentrate or antithrombin-containing blood&#xD;
             product other than the study medication within 14 days of either of the two phases of&#xD;
             the study&#xD;
&#xD;
         10. Prior diagnosis of heparin-induced thrombocytopenia&#xD;
&#xD;
         11. TE or TEE within the last 6 months&#xD;
&#xD;
         12. Female patients who are nursing&#xD;
&#xD;
         13. Have participated in another investigational study within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sigurd Knaub</last_name>
    <phone>+41554512141</phone>
    <email>Sigurd.Knaub@octapharma.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombin III Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

